Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RIGL NASDAQ:SPPI NASDAQ:VSTM NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRIGLRigel Pharmaceuticals$38.85-1.2%$26.17$12.66▼$43.72$705.12M1.21962,224 shs846,456 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AVSTMVerastem$9.25+0.2%$6.18$2.34▼$9.43$569.29M0.832.97 million shs1.46 million shsZBIOZenas BioPharma$16.00-1.6%$13.96$5.83▼$26.25$684.71MN/A164,474 shs143,136 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRIGLRigel Pharmaceuticals-1.17%-6.39%+84.91%+101.30%+201.16%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%VSTMVerastem+0.22%+1.87%+48.48%+24.16%+280.66%ZBIOZenas BioPharma-1.60%-6.43%+1.59%+67.89%+1,599,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRIGLRigel Pharmaceuticals1.5858 of 5 stars1.21.00.00.02.61.73.1SPPISpectrum Pharmaceuticals0.3185 of 5 stars0.00.00.04.70.00.00.6VSTMVerastem3.0702 of 5 stars3.53.00.00.03.12.50.6ZBIOZenas BioPharma1.5335 of 5 stars3.50.00.00.02.00.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRIGLRigel Pharmaceuticals 2.40Hold$38.20-1.67% DownsideSPPISpectrum Pharmaceuticals 0.00N/AN/AN/AVSTMVerastem 3.00Buy$13.2943.63% UpsideZBIOZenas BioPharma 3.00Buy$36.67129.17% UpsideCurrent Analyst Ratings BreakdownLatest SPPI, RIGL, ZBIO, and VSTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025VSTMVerastemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/12/2025VSTMVerastemZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold8/8/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$12.00 ➝ $13.008/6/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$23.00 ➝ $32.006/25/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRIGLRigel Pharmaceuticals$179.28M3.89$1.07 per share36.44$4.57 per share8.50SPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87VSTMVerastem$2.14M266.40N/AN/A$0.59 per share15.68ZBIOZenas BioPharma$5M134.75N/AN/A$5.69 per share2.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRIGLRigel Pharmaceuticals$17.49M$5.417.1837.00N/A36.51%438.89%57.03%11/6/2025 (Estimated)SPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/AVSTMVerastem-$130.64M-$3.28N/AN/AN/AN/A-2,003.62%-119.85%11/5/2025 (Estimated)ZBIOZenas BioPharma-$156.99M-$3.55N/A∞N/AN/A-59.21%-50.56%11/11/2025 (Estimated)Latest SPPI, RIGL, ZBIO, and VSTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ZBIOZenas BioPharma-$1.02-$1.25-$0.23-$1.25$5.00 millionN/A8/7/2025Q2 2025VSTMVerastem-$0.64-$0.39+$0.25-$0.39$6.01 million$2.14 million8/5/2025Q2 2025RIGLRigel Pharmaceuticals$1.97$3.28+$1.31$3.28$64.58 million$101.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/AZBIOZenas BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRIGLRigel Pharmaceuticals0.462.021.90SPPISpectrum PharmaceuticalsN/A2.712.38VSTMVerastem2.063.463.44ZBIOZenas BioPharmaN/A5.235.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRIGLRigel Pharmaceuticals66.23%SPPISpectrum Pharmaceuticals21.67%VSTMVerastem88.37%ZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipRIGLRigel Pharmaceuticals9.48%SPPISpectrum Pharmaceuticals2.70%VSTMVerastem2.10%ZBIOZenas BioPharma16.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRIGLRigel Pharmaceuticals16017.94 million16.24 millionOptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableVSTMVerastem5061.55 million60.25 millionOptionableZBIOZenas BioPharmaN/A42.11 million35.16 millionN/ASPPI, RIGL, ZBIO, and VSTM HeadlinesRecent News About These CompaniesZenas BioPharma to Present at Upcoming Healthcare Investor ConferencesAugust 26, 2025 | globenewswire.comZenas BioPharma (NASDAQ:ZBIO) Trading Down 7.2% - Here's What HappenedAugust 21, 2025 | marketbeat.comWe Think Zenas BioPharma (NASDAQ:ZBIO) Needs To Drive Business Growth CarefullyAugust 20, 2025 | finance.yahoo.comZenas BioPharma (NASDAQ:ZBIO) Trading 8.1% Higher - Should You Buy?August 20, 2025 | marketbeat.comHC Wainwright Lowers Earnings Estimates for Zenas BioPharmaAugust 17, 2025 | marketbeat.comWhat is Wedbush's Estimate for Zenas BioPharma Q3 Earnings?August 17, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Rating Lowered to Sell at Wall Street ZenAugust 17, 2025 | marketbeat.comZenas BioPharma (ZBIO) Expected to Announce Quarterly Earnings on ThursdayAugust 15, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Issues Earnings ResultsAugust 14, 2025 | marketbeat.comZenas BioPharma Faces Legal and Financial Challenges Amid Securities Class Action LawsuitAugust 13, 2025 | msn.comZenas BioPharma Reports Q2 2025 Financial ResultsAugust 13, 2025 | tipranks.comZenas BioPharma expects cash to fund operations into Q4 of 2026August 12, 2025 | msn.comZenas BioPharma reports Q2 EPS ($1.25) vs ($24.23) last yearAugust 12, 2025 | msn.comZenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 12, 2025 | globenewswire.com44,067 Shares in Zenas BioPharma, Inc. (NASDAQ:ZBIO) Purchased by Jefferies Financial Group Inc.August 9, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Down 8.8% - Should You Sell?August 6, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Up 10.2% - What's Next?August 5, 2025 | marketbeat.com3 Highly Shorted Stocks That Could Be the Next Wall Street SensationsAugust 2, 2025 | msn.comZenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MSJuly 28, 2025 | seekingalpha.comInnovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharmaJuly 3, 2025 | tipranks.comZenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 20, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPPI, RIGL, ZBIO, and VSTM Company DescriptionsRigel Pharmaceuticals NASDAQ:RIGL$38.85 -0.46 (-1.17%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$38.52 -0.33 (-0.85%) As of 08/29/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Spectrum Pharmaceuticals NASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Verastem NASDAQ:VSTM$9.25 +0.02 (+0.22%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$9.18 -0.07 (-0.80%) As of 08/29/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.Zenas BioPharma NASDAQ:ZBIO$16.00 -0.26 (-1.60%) As of 08/29/2025 04:00 PM EasternZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
